In brief
- A Stanford University trial combines a single ketamine infusion with daily microdoses of buprenorphine for four weeks
- 78% of those who received buprenorphine maintained improvement at one month, compared to 48% with a placebo
- The findings were published on May 18, 2026, in the American Journal of Psychiatry
A ketamine infusion can extinguish urgent suicidal thoughts in a matter of hours, but that relief is typically short-lived—often lasting only about a week before symptoms begin to resurface. A team at Stanford Medicine, led by psychiatrist Alan Schatzberg along with Jason Tucciarone and Igor Bandeira, has tested a simple way to extend that window: adding very low doses of buprenorphine in the days following the infusion.
How the trial was designed
The randomized, double-blind, placebo-controlled study included 45 people with major depressive disorder and active suicidal ideation. All participants received the same 40-minute intravenous ketamine infusion. Starting 48 hours later, half the group took sublingual buprenorphine tablets for four weeks, beginning at 0.2 mg daily for the first week and increasing to 0.8 mg by the fourth; the other half received an identical placebo. These amounts are equivalent to just 5–10% of the doses typically used to treat pain, and far below those used in managing opioid dependence.
A one-month difference compared to placebo
After four weeks, 78% of those who took buprenorphine remained responsive to the treatment, compared to 48% in the placebo group. On the suicidal ideation scale, the buprenorphine group averaged a score of 3.6, below the clinical risk threshold (6), while the placebo group sat at 8.7, well within the range of concern. The researchers summarize it this way: patients who had long struggled with thoughts of dying noticed relief “within a day” and, with the buprenorphine, were able to “build on that relief for four weeks.” Interestingly, the drug did not significantly boost the general antidepressant effect of ketamine; its contribution appears limited, and very specific, to sustaining the reduction of suicidal ideation.
What it implies
This was a small-scale trial (45 people), so larger replications are needed before the combination can be considered standard practice. It is also unknown whether extending buprenorphine beyond four weeks would prolong the benefit, how it would perform in bipolar depression, or the exact mechanism by which it acts. Even so, the result points to a low-cost, low-risk path—using doses far below those for analgesia or opioid substitution—to sustain one of ketamine’s most valuable effects: the ability to cut a suicide crisis off at the root while more durable, long-term treatments are adjusted.
Source
- Stanford Medicine. Drug combo is the first to prolong ketamine’s antisuicide effects. Stanford Medicine News, May 18, 2026 (study published in American Journal of Psychiatry).
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
